glp-1 drugs shortage FDA says that the is over Hims & Hers stock falls

Sales of antiobesity drugs hit $1.1 billion in the second quarter of 2023.

As the FDA cracks down on compounded formulasof weight loss drugs such as Wegovy (semaglutide) and Zepbound (tirzepatide),Americans are turning to unregulated GLP-1 dietary supplements that claim to supercharge the bodys GLP-1 levels to accelerate weight loss.Sold as gummies, powders, patches, and capsules, these products are cheaper, over-the-counter alternatives.Although these supplements arent a recent medical breakthrough, they are getting a lot of attention from experts

Beyond these metabolic benefits, accumulating evidence indicates that GLP-1RAs exert immunomodulatory effects, including suppression of pro-inflammatory cytokines, enhancement of regulatory T-cell function, and improvements in adipose tissue and gut-derived immune signaling

Farxiga can cost up to $600 without insurance, depending on the pharmacy and brand choice